What effective technique to differentiate radiation brain necrosis from a tumor progression in patients treated with radiation: A monocentric retrospective study combining the MRI TRAMs technique and the (18F)-dopa PET/CT

Purpose. - Brain necrosis after radiotherapy is a challenging diagnosis, since it has similar radiological appearance on standard MRI to tumor progression. Consequences on treatment decisions can be impor-tant. We compare recent imaging techniques in order to adopt a reliable diagnostic protocol in doubtful situations.Patients and method. - This is a retrospective study comparing the performance of three imaging tech-niques after radiotherapy of brain metastasis: Perfusion-MRI, TRAMs technique and F-dopa PET-CT. The evolution of the treated metastasis volume was also analyzed by contouring all patients MRIs. All included patients were suspected of relapse and had the three exams once the volume of treated metastasis increased.Results. - The majority of our patients were treated by stereotactic radiotherapy. Suspicion of relapse was on average around 17 months after treatment. Four cases of radionecrosis were diagnosed and six cases of real tumor progression. Neurological symptoms were less present in radionecrosis cases. All of our radionecrosis cases had relative cerebral blood volume below 1. F-dopa PET-CT succeeded to set the good diagnosis in eight cases, although we found one false positive and one false negative exam. The TRAMs technique failed in one case of false negative exam.Conclusions. - Perfusion-MRI showed high performance in the diagnosis of radionecrosis, especially when calculating relative cerebral blood volume rate. The TRAMs technique showed interesting results and deserves application in daily routine combined with the perfusion-MRI. F-dopa CT might induce false results because of different metabolic uptake according to tumor type, medication and brain blood barrier leak.& COPY; 2023 Socie & PRIME;te & PRIME; franc,aise de radiothe & PRIME;rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.